Pharma Pressreleases

This section covers the managerial aspects in the Pharma industry.

European Medicines Agency Validates the Marketing Authorization Application for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma

Monday, October 31, 2016
PR Newswire

DARMSTADT Germany and NEW YORK October 31 2016 PRNewswire If approved avelumab an investigational antiPDL1 IgG1 could be the first treatment indicated for patients with metastatic Merkel cell carcinoma TheMarketing Authorization Applicationis based on Phase II datafrom the JAVELIN Merkel 200 s..

Arix Bioscience Appoints Dr Franz B Humer as Senior Independent Director

Monday, October 31, 2016
PR Newswire

LONDON October 31 2016 PRNewswire Arix Bioscience plc Arix Bioscience a global healthcare and life science company supporting medical innovation announced today that it had appointed Dr Franz B Humer as its Senior Independent Director Dr Humer is one of the pharmaceutical industrys most respect..

New Engineered Spider Silk has Potential to Unseat Dragon Silk as World\'s Strongest Recombinant Silk Fiber

Monday, October 31, 2016
GLOBE NEWSWIRE

ANN ARBOR Mich Oct 31 2016 GLOBE NEWSWIRE Kraig Biocraft Laboratories Inc OTCQBKBLB Company the leading developer of spider silk based fibers today announced it has created a new line of genetically engineered silkworms that rival the Companys Dragon Silkfor the title as worlds strongest and m..

Karyopharm to Report Third Quarter 2016 Financial Results on November 7, 2016

Monday, October 31, 2016
GLOBE NEWSWIRE

NEWTON Mass Oct 31 2016 GLOBE NEWSWIRE Karyopharm Therapeutics Inc NasdaqKPTI a clinicalstage pharmaceutical company announced today that it will report third quarter 2016 financial results and provide a company update on Monday November 7 2016 Karyopharms management team will host a conferenc..

InMed Pharmaceuticals, Inc. Appoints Senior Vice President, Clinical and Regulatory Affairs

Monday, October 31, 2016
PR Newswire

CSE IN OTCQB IMLFF VANCOUVER Oct 31 2016 PRNewswire InMed Pharmaceuticals Inc InMed CSE IN OTCQB IMLFF today announced the appointment of Alexandra DJ Mancini MSc as Senior Vice President Clinical and Regulatory Affairs Ms Mancini has over 30 years global biopharmaceutical RD experience with ..

New Edition of Online Tool to Measure Cancer Progress to Launch at World Cancer Congress

Monday, October 31, 2016
PR Newswire

PARIS Oct 31 2016 PRNewswire The 2016 World Cancer Congress WCC in Paris a global gathering of more than 3500 cancer experts will be the setting for the introduction of a new enhanced version of the PACE Continuous Innovation Indicators CII by PACE Patient Access to Cancer care Excellence a Lil..

NanoViricides Signs Agreement with SUNY Upstate Medical Center for Testing of Its Drug Candidates for the Treatment of Shingles

Monday, October 31, 2016
PR Newswire

SHELTON Conn Oct 31 2016 PRNewswire NanoViricides Inc NYSE MKT NNVC the Company announced today that it has entered into an agreement with SUNY Upstate Medical University for the testing of its nanoviricides drug candidates against varicella zoster virus ie the shingles virus The research will ..

BrainStorm Granted United States Patent for its Stem Cell Technology

Monday, October 31, 2016
PR Newswire

HACKENSACK NJand PETACH TIKVAHIsrael Oct31 2016 PRNewswire BrainStorm Cell Therapeutics IncNASDAQ BCLI a leading developer of adult stem cell therapeutics for neurodegenerative diseases announced that it has been granted United States Patent No 9474787titled Mesenchymal Stem Cells for the Treatme..

AcelRx Pharmaceuticals to Present ARX-04 Analysis for Treatment of Moderate-to-Severe Acute Pain in Obese Patients at The Obesity Society Annual Meeting

Monday, October 31, 2016
PR Newswire

REDWOOD CITY Calif Oct 31 2016 PRNewswire AcelRx Pharmaceuticals Inc NASDAQ ACRX a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderatetosevere acute pain announced an upcoming poster presentation at The Obesity So..

Zimmer Biomet Reports Third Quarter 2016 Financial Results

Monday, October 31, 2016
PR Newswire

WARSAW Ind Oct 31 2016 PRNewswire Zimmer Biomet Holdings Inc NYSE and SIXZBH today reported financial results for the quarter ended September 30 2016 The Company reported third quarter net sales of 183 billion an increase of 40 compared to the third quarter of 2015 On an adjusted constant currency..

Merrimack Announces Acceptance for Review of ANDA filed by Actavis for Generic Doxorubicin Hydrochloride Liposome Injection (aka DOXIL®)

Monday, October 31, 2016
PR Newswire

CAMBRIDGE Mass Oct 31 2016 PRNewswire Merrimack Pharmaceuticals IncNASDAQ MACK today announced that the US Food and Drug Administration FDA has accepted for review the Abbreviated New Drug Application ANDA for generic doxorubicin hydrochloride HCI liposome injection submitted by its partner Actavi..

Pioneering Drug Discovery Company Bridge Medicines Launched to Advance Promising Early Technologies in Major Academic Institutions through Human Proof of Concept

Monday, October 31, 2016
PR Newswire

NEW YORK and OSAKA Japan Oct 31 2016 PRNewswire Memorial Sloan Kettering Cancer Center The Rockefeller University and Weill Cornell Medicine announced today that they have established a new drug discovery company called Bridge Medicines Launched in partnership with Takeda Pharmaceutical Company Lt..

Zydus to Present New Scientific Data of Investigational Saroglitazar at the 2016 AASLD Liver Meeting in Boston, USA

Monday, October 31, 2016
PR Newswire

AHMEDABAD India October 31 2016 PRNewswire Zydus Cadila today announced that new data of Saroglitazar will be presented at The Liver Meeting being held at the John B Hynes Veterans Memorial Convention Center Boston from 11th to 15th of November 2016 Scientific abstract describing the attenuatin..

AbbVie to Present at the 25th Annual Credit Suisse Healthcare Conference

Monday, October 31, 2016
PR Newswire

NORTH CHICAGO Ill Oct 31 2016 PRNewswire AbbVie NYSE ABBV will participate in the 25th Annual Credit Suisse Healthcare Conference on Tuesday November 8 2016 Richard Gonzalez chairman of the board and chief executive officer will participate in a question and answer session at 1200 pm Central time..

Bio-Techne Declares Dividend

Monday, October 31, 2016
PR Newswire

MINNEAPOLIS Oct 31 2016 PRNewswire BioTechne Corporation NASDAQTECH announced that its Board of Directors has decided to pay a dividend of 032 per share for the quarter ended September 30 2016 The quarterly dividend will be payable November 28 2016 to all common shareholders of record on November ..

Infinity Announces The Date Of Its Third Quarter 2016 Financial Results Conference Call And Webcast

Monday, October 31, 2016
PR Newswire

CAMBRIDGE Mass Oct 31 2016 PRNewswire Infinity Pharmaceuticals Inc NASDAQ INFI will host a conference call on Monday November 7 2016 at 430 pm ET During the call management will review the companys third quarter 2016 financial results and provide an update on Infinitys business A live webcast of..

Now Enrolling: Global Phase 3 Clinical Study to Evaluate Eisai\'s BACE Inhibitor in Early Alzheimer\'s Disease

Monday, October 31, 2016
PR Newswire

WOODCLIFF LAKE NJ Oct 31 2016 PRNewswire Eisai Inc announced today that enrollment has begun in the USfor MISSIONAD a Phase 3 clinical program for E2609 a Betasecretase Cleaving Enzyme BACE inhibitor for patients with early Alzheimers disease E2609 was discovered by Eisai and is being jointly deve..

Eisai Initiates Phase 2 Clinical Trial to Evaluate Lemborexant in the Treatment of Irregular Sleep-Wake Rhythm Disorder (ISWRD) in Dementia Patients

Monday, October 31, 2016
PR Newswire

WOODCLIFF LAKE NJ and STAMFORD Conn Oct31 2016 PRNewswire Eisai Inc and Purdue Pharma LP announced today the initiation of a multicenter randomized Phase 2 clinical study Study 202 to evaluate Eisais internallydiscovered oral dual orexin receptor antagonist lemborexant E2006 in patients with mild ..

Regen BioPharma, Inc. Discusses Next Steps in its NR2F6 Small Molecule Program

Monday, October 31, 2016
PR Newswire

SAN DIEGO October 31 2016 PRNewswire Regen BioPharma Inc OTCQB RGBP OTCQB RGBPP today announced its strategy for developing its novel NR2F6 small molecule modulators Regen has recently filed a composition of matter patent application covering these novel NR2F6 small molecule modulators Having r..

Galmed Pharmaceuticals Third Quarter 2016 Conference Call and Webcast Scheduled for Monday, November 7th, 2016

Monday, October 31, 2016
PR Newswire

TEL AVIV Israel Oct 31 2016 PRNewswire Galmed Pharmaceuticals Ltd Nasdaq GLMD Galmed or the Company a clinicalstage biopharmaceutical company focused on the development of a oncedaily oral therapy for the treatment of liver diseases announced today that it will host a conference call and webcast ..

TOP